Mallinckrodt Study Shows Acthar Primary Endpoint Not Met in Patients with Persistently Active Systemic Lupus Erythematosus

By: via Benzinga
Data presented yesterday by researchers for Mallinckrodt plc (NYSE: MNK) suggest that H.P. Acthar® Gel (repository corticotropin ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.